Innovations in Airway Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: 15 January 2025 | Viewed by 1952

Special Issue Editor


E-Mail Website
Guest Editor
1. Faculty of Nursing, University of Thessaly, 41500 Larissa, Greece
2. Respiratory Medicine Department, Faculty of Medicine, University of Thessaly, 41110 Larissa, Greece
Interests: human pathophysiology; clinical and medical research; medical education
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Background and history of this topic: This Special Issue on "Innovations in Airway Diseases" aims to provide a comprehensive overview of the latest advances in research, diagnosis, and treatment of airway diseases. This field has witnessed significant progress over the past decades, influenced by technological advances and a deeper understanding of the biological underpinnings of airway pathophysiology. By bringing together leading experts and researchers, this issue seeks to highlight the innovative approaches that are shaping the future of respiratory medicine.

Historical Context and Evolution: The background and history of airway diseases are marked by pivotal discoveries that have transformed patient outcomes. From the development of bronchodilators to the advent of personalized medicine based on genetic profiles, the journey of airway disease management reflects a broader narrative of medical advancement. This section of the issue will trace these developments, setting the stage for a discussion on how historical insights are being integrated into modern therapeutic strategies.

Aim and Scope of the Issue: The primary aim of this Special Issue is to encapsulate the cutting-edge research that represents the frontier of knowledge in the field of airway diseases. It is particularly focused on novel diagnostic techniques, therapeutic interventions, and prognostic assessment tools that have emerged in recent years. The scope of this issue extends to molecular biology, clinical trials, and patient-centered care approaches, aiming to cover a broad spectrum of topics that promise to redefine standards and improve clinical outcomes.

Showcasing Cutting-edge Research: By highlighting recent innovations, this section of the Special Issue will focus on groundbreaking research that offers new insights into the mechanisms of airway diseases. It will feature studies on immune modulation, the impact of environmental factors on airway health, and advancements in biotechnology that facilitate more precise interventions. Contributions will include detailed analyses of clinical trial data, reviews of emerging therapies, and discussions on the potential of new research methodologies to address unresolved challenges in the field.

Call for Papers and Contribution: In pursuit of expanding the discourse within this field, this issue invites submissions from a diverse array of scholarly contributions. Desired articles include original research papers that introduce new findings, comprehensive review articles that provide in-depth insights into current knowledge, and case studies that explore innovative treatment applications. This call for papers emphasizes the importance of contributions that not only present scientific rigor but also propose practical implications for clinical practice, aiming to foster a richer understanding and enhanced therapeutic approaches in the treatment of airway diseases.

Dr. Ourania S. Kotsiou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • airway pathophysiology
  • respiratory therapeutics
  • novel diagnostic techniques
  • personalized medicine
  • clinical trials in airway diseases
  • innovative treatment strategies
  • molecular mechanisms
  • biotechnological advances
  • environmental impacts
  • advanced diagnostic tools

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1384 KiB  
Article
Detection and Characterization of Extracellular Vesicles in Sputum Samples of COPD Patients
by Ourania S. Kotsiou, Katerina Katsanaki, Aikaterini Tsiggene, Sophia Papathanasiou, Erasmia Rouka, Dionysios Antonopoulos, Irene Gerogianni, Nikolaos A. A. Balatsos, Konstantinos I. Gourgoulianis and Irene Tsilioni
J. Pers. Med. 2024, 14(8), 820; https://doi.org/10.3390/jpm14080820 - 1 Aug 2024
Viewed by 1160
Abstract
Background: Only one study has reported the presence of extracellular vesicles (EVs) in COPD patients’ sputum. Thus, we aimed to isolate and characterize EVs from COPD and healthy individuals’ sputum. Methods: A total of 20 spontaneous sputum samples from COPD patients (m/f: 19/1) [...] Read more.
Background: Only one study has reported the presence of extracellular vesicles (EVs) in COPD patients’ sputum. Thus, we aimed to isolate and characterize EVs from COPD and healthy individuals’ sputum. Methods: A total of 20 spontaneous sputum samples from COPD patients (m/f: 19/1) and induced sputum samples from healthy controls (m/f: 8/2) were used for EV isolation. The sputum supernatants were resuspended in PBS, precleared by centrifugation at 800× g for 10 min at 4 °C, and passed through a 0.22 μm filter (Millipore, Burlington, MA, USA). EVs were isolated by a standard membrane affinity spin column method (exoEasy maxi kit, Qiagen, Hilden, Germany). The EVs were then characterized by assessing their morphology and size using Transmission Electron Microscopy (TEM) and determining the CD9 and CD81 EV-markers with Western blot analysis. Results: The EVs had a spherical shape and their mean diameter in the COPD patients was significantly greater than in the controls. Enrichment of the EV markers, CD9 and CD81, were detected in both the healthy and COPD individuals. Total EV-associated protein was significantly increased in the COPD patients compared to the controls. ROC analysis showed that total EV-associated protein in the sputum could be used to differentiate between the controls and COPD patients, with a sensitivity of 80% and a specificity of 70% at a cut-off point of 55.59 μg/mL (AUC = 0.8150). Conclusions: EVs were detectable in both the COPD and healthy individuals’ sputum. The ratio of EVs in the 150–200 nm range was twice as high in the COPD patients than in the controls. The COPD patients’ sputum contained increased total EV-associated protein as compared to controls, highlighting their value as a new source of specific exoproteins. Full article
(This article belongs to the Special Issue Innovations in Airway Diseases)
Show Figures

Figure 1

Back to TopTop